{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:48:28Z","timestamp":1789742908221,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2014.150","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T12:51:11Z","timestamp":1398948671000},"page":"e1201-e1201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases"],"prefix":"10.1038","volume":"5","author":[{"given":"M","family":"Farhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Poissonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ouk-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-D","family":"Brion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Alami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Feuillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Jayat-Vignoles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"key":"BFcddis2014150_CR1","doi-asserted-by":"publisher","first-page":"R795","DOI":"10.1016\/S0960-9822(01)00474-2","volume":"11","author":"PM Henson","year":"2001","unstructured":"Henson PM, Bratton DL, Fadok VA . Apoptotic cell removal. Curr Biol 2001; 11: R795\u2013R805.","journal-title":"Curr Biol"},{"key":"BFcddis2014150_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.1099320","volume":"305","author":"DR Green","year":"2004","unstructured":"Green DR, Kroemer G . The pathophysiology of mitochondrial cell death. Science 2004; 305: 626\u2013629.","journal-title":"Science"},{"key":"BFcddis2014150_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99\u2013163.","journal-title":"Physiol Rev"},{"key":"BFcddis2014150_CR4","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.1038\/onc.2008.302","volume":"27","author":"EC LaCasse","year":"2008","unstructured":"LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG . IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252\u20136275.","journal-title":"Oncogene"},{"key":"BFcddis2014150_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1124\/mi.11.2.12","volume":"11","author":"DR Matson","year":"2011","unstructured":"Matson DR, Stukenberg PT . Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2011; 11: 141\u2013150.","journal-title":"Mol Interv"},{"key":"BFcddis2014150_CR6","first-page":"497","volume":"16","author":"A Basu","year":"2000","unstructured":"Basu A, You SA, Haldar S . Regulation of Bcl2 phosphorylation by stress response kinase pathway. Int J Oncol 2000; 16: 497\u2013500.","journal-title":"Int J Oncol"},{"key":"BFcddis2014150_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/157488406775268200","volume":"1","author":"IE Kuppens","year":"2006","unstructured":"Kuppens IE . Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 2006; 1: 57\u201370.","journal-title":"Curr Clin Pharmacol"},{"key":"BFcddis2014150_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L . Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253\u2013265.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2014150_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C R\u00e9cher","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, Molina TJ, Ferm\u00e9 C, Casasnovas O et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858\u20131867.","journal-title":"Lancet"},{"key":"BFcddis2014150_CR10","first-page":"371","volume":"6","author":"JA Yared","year":"2012","unstructured":"Yared JA, Tkaczuk KHR . Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 2012; 6: 371\u2013384.","journal-title":"Drug Des Devel Ther"},{"key":"BFcddis2014150_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1212\/WNL.47.1.115","volume":"47","author":"RJ Freilich","year":"1996","unstructured":"Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM . Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115\u2013118.","journal-title":"Neurology"},{"issue":"Suppl 5","key":"BFcddis2014150_CR12","doi-asserted-by":"publisher","first-page":"v3","DOI":"10.1093\/annonc\/mdm172","volume":"18","author":"T Fojo","year":"2007","unstructured":"Fojo T, Menefee M . Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007; 18 (Suppl 5): v3\u2013v8.","journal-title":"Ann Oncol"},{"key":"BFcddis2014150_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1517\/13543784.9.4.779","volume":"9","author":"C Dumontet","year":"2000","unstructured":"Dumontet C . Mechanisms of action and resistance to tubulin-binding agents. Expert Opin Investig Drugs 2000; 9: 779\u2013788.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFcddis2014150_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/157489207779561462","volume":"2","author":"SX Cai","year":"2007","unstructured":"Cai SX . Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007; 2: 79\u2013101.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"BFcddis2014150_CR15","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1158\/1535-7163.MCT-06-0429","volume":"5","author":"P Thomson","year":"2006","unstructured":"Thomson P, Naylor MA, Everett SA, Stratford MRL, Lewis G, Hill S et al. Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4. Mol Cancer Ther 2006; 5: 2886\u20132894.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2014150_CR16","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1021\/jm900321u","volume":"52","author":"S Messaoudi","year":"2009","unstructured":"Messaoudi S, Tr\u00e9guier B, Hamze A, Provot O, Peyrat JF, De Losada JR et al. Isocombretastatins a versus combretastatins a: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. J Med Chem 2009; 52: 4538\u20134542.","journal-title":"J Med Chem"},{"key":"BFcddis2014150_CR17","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/cmdc.200900290","volume":"4","author":"A Hamze","year":"2009","unstructured":"Hamze A, Giraud A, Messaoudi S, Provot O, Peyrat J-F, Bignon J et al. Synthesis, biological evaluation of 1,1-diarylethylenes as a novel class of antimitotic agents. ChemMedChem 2009; 4: 1912\u20131924.","journal-title":"ChemMedChem"},{"key":"BFcddis2014150_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10549-011-1875-6","volume":"133","author":"J Cortes","year":"2012","unstructured":"Cortes J, Vidal M . Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat 2012; 133: 821\u2013830.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcddis2014150_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/leu.2013.274","volume":"28","author":"A Chanut","year":"2014","unstructured":"Chanut A, Duguet F, Marfak A, David A, Petit B, Parrens M et al. RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells. Leukemia 2014; 28: 871\u2013879.","journal-title":"Leukemia"},{"key":"BFcddis2014150_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/351453a0","volume":"351","author":"AJ Levine","year":"1991","unstructured":"Levine AJ, Momand J, Finlay CA . The p53 tumour suppressor gene. Nature 1991; 351: 453\u2013456.","journal-title":"Nature"},{"key":"BFcddis2014150_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP . Cancer. p53, guardian of the genome. Nature 1992; 358: 15\u201316.","journal-title":"Nature"},{"key":"BFcddis2014150_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s000180050265","volume":"55","author":"M Oren","year":"1999","unstructured":"Oren M, Rotter V . Introduction: p53\u2014the first twenty years. Cell Mol Life Sci 1999; 55: 9\u201311.","journal-title":"Cell Mol Life Sci"},{"key":"BFcddis2014150_CR23","doi-asserted-by":"publisher","first-page":"d151","DOI":"10.2741\/A772","volume":"7","author":"X Wu","year":"2002","unstructured":"Wu X, Deng Y . Bax and BH3-domain-only proteins in p53-mediated apoptosis. Front Biosci 2002; 7: d151\u2013d156.","journal-title":"Front Biosci"},{"key":"BFcddis2014150_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.bbrc.2005.03.189","volume":"331","author":"J Yu","year":"2005","unstructured":"Yu J, Zhang L . The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331: 851\u2013858.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2014150_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sj.cdd.4401227","volume":"10","author":"JK Sax","year":"2003","unstructured":"Sax JK, El-Deiry WS . p53 downstream targets and chemosensitivity. Cell Death Differ 2003; 10: 413\u2013417.","journal-title":"Cell Death Differ"},{"key":"BFcddis2014150_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","volume":"146","author":"K-JJ Cheung","year":"2009","unstructured":"Cheung K-JJ, Horsman DE, Gascoyne RD . The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009; 146: 257\u2013269.","journal-title":"Br J Haematol"},{"key":"BFcddis2014150_CR27","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood.V84.8.2412.2412","volume":"84","author":"J Imamura","year":"1994","unstructured":"Imamura J, Miyoshi I, Koeffler HP . p53 in hematologic malignancies. Blood 1994; 84: 2412\u20132421.","journal-title":"Blood"},{"key":"BFcddis2014150_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/BSR20110125","volume":"32","author":"D Lai","year":"2012","unstructured":"Lai D, Visser-Grieve S, Yang X . Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 2012; 32: 361\u2013374.","journal-title":"Biosci Rep"},{"key":"BFcddis2014150_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.drup.2006.03.001","volume":"9","author":"Q Yu","year":"2006","unstructured":"Yu Q . Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat 2006; 9: 19\u201325.","journal-title":"Drug Resist Updat"},{"key":"BFcddis2014150_CR30","first-page":"978312","volume":"2011","author":"K Suzuki","year":"2011","unstructured":"Suzuki K, Matsubara H . Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011; 2011: 978312.","journal-title":"J Biomed Biotechnol"},{"key":"BFcddis2014150_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RSY Wong","year":"2011","unstructured":"Wong RSY . Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011; 30: 87.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFcddis2014150_CR32","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/jnci\/91.9.772","volume":"91","author":"XH Zhu","year":"1999","unstructured":"Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772\u2013778.","journal-title":"J Natl Cancer Inst"},{"key":"BFcddis2014150_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1158\/1535-7163.MCT-04-0206","volume":"4","author":"Y Li","year":"2005","unstructured":"Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL . Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 2005; 4: 901\u2013909.","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"BFcddis2014150_CR34","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/onc.2009.45","volume":"27","author":"J Yu","year":"2008","unstructured":"Yu J, Zhang L . PUMA, a potent killer with or without p53. Oncogene 2008; 27 (Suppl 1): S71\u2013S83.","journal-title":"Oncogene"},{"key":"BFcddis2014150_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.bbrc.2005.03.184","volume":"331","author":"M Corazzari","year":"2005","unstructured":"Corazzari M, Lovat PE, Oliverio S, Di Sano F, Donnorso RP, Redfern CPF et al. Fenretinide: a p53-independent way to kill cancer cells. Biochem Biophys Res Commun 2005; 331: 810\u2013815.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2014150_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1476-4598-12-35","volume":"12","author":"CA Taylor","year":"2013","unstructured":"Taylor CA, Zheng Q, Liu Z, Thompson JE . Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells. Mol Cancer 2013; 12: 35.","journal-title":"Mol Cancer"},{"key":"BFcddis2014150_CR37","first-page":"1147","volume":"43","author":"G Henle","year":"1969","unstructured":"Henle G, Henle W, Clifford P, Diehl V, Kafuko GW, Kirya BG et al. Antibodies to Epstein-Barr virus in Burkitt\u2019s lymphoma and control groups. J Natl Cancer Inst 1969; 43: 1147\u20131157.","journal-title":"J Natl Cancer Inst"},{"key":"BFcddis2014150_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","volume":"1","author":"DA Thorley-Lawson","year":"2001","unstructured":"Thorley-Lawson DA . Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1: 75\u201382.","journal-title":"Nat Rev Immunol"},{"key":"BFcddis2014150_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1098\/rstb.2000.0781","volume":"356","author":"GW Bornkamm","year":"2001","unstructured":"Bornkamm GW, Hammerschmidt W . Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001; 356: 437\u2013459.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"BFcddis2014150_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1040-8428(02)00078-1","volume":"45","author":"JM Middeldorp","year":"2003","unstructured":"Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ . Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 2003; 45: 1\u201336.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFcddis2014150_CR41","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4049\/jimmunol.162.5.2555","volume":"162","author":"LK Busch","year":"1999","unstructured":"Busch LK, Bishop GA . The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes. J Immunol 1999; 162: 2555\u20132561.","journal-title":"J Immunol"},{"key":"BFcddis2014150_CR42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0165-6147(97)01097-3","volume":"18","author":"J Eder","year":"1997","unstructured":"Eder J . Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? Trends Pharmacol Sci 1997; 18: 319\u2013322.","journal-title":"Trends Pharmacol Sci"},{"key":"BFcddis2014150_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0898-6568(02)00083-9","volume":"15","author":"N Lam","year":"2003","unstructured":"Lam N, Sugden B . CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 2003; 15: 9\u201316.","journal-title":"Cell Signal"},{"key":"BFcddis2014150_CR44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.14712\/fb2005051060188","volume":"51","author":"F Sandor","year":"2005","unstructured":"Sandor F, Buc M . Toll-like receptors. II. Distribution and pathways involved in TLR signalling. Folia Biol (Praha) 2005; 51: 188\u2013197.","journal-title":"Folia Biol (Praha)"},{"key":"BFcddis2014150_CR45","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2005-05-2053","volume":"107","author":"C Le Clorennec","year":"2006","unstructured":"Le Clorennec C, Youlyouz-Marfak I, Adriaenssens E, Coll J, Bornkamm GW, Feuillard J . EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53. Blood 2006; 107: 2070\u20132078.","journal-title":"Blood"},{"key":"BFcddis2014150_CR46","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1128\/JVI.02250-07","volume":"82","author":"C Le Clorennec","year":"2008","unstructured":"Le Clorennec C, Ouk TS, Youlyouz-Marfak I, Panteix S, Martin C-C, Rastelli J et al. Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95\/Fas with caspase 8-mediated apoptosis. J Virol 2008; 82: 6721\u20136733.","journal-title":"J Virol"},{"key":"BFcddis2014150_CR47","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1073\/pnas.0438011100","volume":"100","author":"K Lei","year":"2003","unstructured":"Lei K, Davis RJ . JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432\u20132437.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"BFcddis2014150_CR48","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1038\/onc.2009.42","volume":"27","author":"JD Pi\u00f1on","year":"2008","unstructured":"Pi\u00f1on JD, Labi V, Egle A, Villunger A . Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008; 27 (Suppl 1): S41\u2013S52.","journal-title":"Oncogene"},{"key":"BFcddis2014150_CR49","doi-asserted-by":"publisher","first-page":"8469","DOI":"10.1128\/MCB.19.12.8469","volume":"19","author":"K Yamamoto","year":"1999","unstructured":"Yamamoto K, Ichijo H, Korsmeyer SJ . BCL-2 is phosphorylated and inactivated by an ASK1\/Jun N-terminal protein kinase pathway normally activated at G(2)\/M. Mol Cell Biol 1999; 19: 8469\u20138478.","journal-title":"Mol Cell Biol"},{"key":"BFcddis2014150_CR50","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.1074\/jbc.M511052200","volume":"281","author":"G De Chiara","year":"2006","unstructured":"De Chiara G, Marcocci ME, Torcia M, Lucibello M, Rosini P, Bonini P et al. Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem 2006; 281: 21353\u201321361.","journal-title":"J Biol Chem"},{"key":"BFcddis2014150_CR51","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.yexcr.2004.05.007","volume":"298","author":"S Grethe","year":"2004","unstructured":"Grethe S, Ares MPS, Andersson T, P\u00f6rn-Ares MI . p38 MAPK mediates TNF-induced apoptosis in endothelial cells via phosphorylation and downregulation of Bcl-x(L). Exp Cell Res 2004; 298: 632\u2013642.","journal-title":"Exp Cell Res"},{"key":"BFcddis2014150_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molcel.2006.07.001","volume":"23","author":"HK Sluss","year":"2006","unstructured":"Sluss HK, Davis RJ . H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation. Mol Cell 2006; 23: 152\u2013153.","journal-title":"Mol Cell"},{"key":"BFcddis2014150_CR53","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1177\/153537020623101012","volume":"231","author":"EH Ahn","year":"2006","unstructured":"Ahn EH, Chang CC, Schroeder JJ . Evaluation of sphinganine and sphingosine as human breast cancer chemotherapeutic and chemopreventive agents. Exp Biol Med (Maywood) 2006; 231: 1664\u20131672.","journal-title":"Exp Biol Med (Maywood)"},{"key":"BFcddis2014150_CR54","first-page":"2881","volume":"30","author":"EH Ahn","year":"2010","unstructured":"Ahn EH, Schroeder JJ . Induction of apoptosis by sphingosine, sphinganine, and C(2)-ceramide in human colon cancer cells, but not by C(2)-dihydroceramide. Anticancer Res 2010; 30: 2881\u20132884.","journal-title":"Anticancer Res"},{"key":"BFcddis2014150_CR55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbabio.2011.03.010","volume":"1807","author":"IR Indran","year":"2011","unstructured":"Indran IR, Tufo G, Pervaiz S, Brenner C . Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 2011; 1807: 735\u2013745.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2014150_CR56","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3892\/ol.2012.928","volume":"4","author":"J Zheng","year":"2012","unstructured":"Zheng J . Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation. Oncol Lett 2012; 4: 1151\u20131157.","journal-title":"Oncol Lett"},{"key":"BFcddis2014150_CR57","doi-asserted-by":"publisher","first-page":"946206","DOI":"10.1155\/2013\/946206","volume":"2013","author":"Z Leni","year":"2013","unstructured":"Leni Z, Parakkal G, Arcaro A . Emerging metabolic targets in the therapy of hematological malignancies. Biomed Res Int 2013; 2013: 946206.","journal-title":"Biomed Res Int"},{"key":"BFcddis2014150_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.1102277","volume":"189","author":"S Durand-Panteix","year":"2012","unstructured":"Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, David A et al. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol 2012; 189: 181\u2013190.","journal-title":"J Immunol"},{"key":"BFcddis2014150_CR59","doi-asserted-by":"publisher","first-page":"14849","DOI":"10.1073\/pnas.222406899","volume":"99","author":"LA Martinez","year":"2002","unstructured":"Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tch\u00e9nio T, Lozano G et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002; 99: 14849\u201314854.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2014150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2014150","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T16:59:05Z","timestamp":1746205145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2014150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"alternative-id":["BFcddis2014150"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2014.150","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]},"assertion":[{"value":"9 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}